Lineage Cell Therapeutics FY2024 EPS Raised by HC Wainwright

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) – Investment analysts at HC Wainwright upped their FY2024 earnings per share estimates for Lineage Cell Therapeutics in a research report issued on Wednesday, December 4th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of ($0.11) per share for the year, up from their previous estimate of ($0.14). HC Wainwright has a “Buy” rating and a $9.00 price objective on the stock. The consensus estimate for Lineage Cell Therapeutics’ current full-year earnings is ($0.09) per share. HC Wainwright also issued estimates for Lineage Cell Therapeutics’ Q4 2024 earnings at ($0.03) EPS, FY2025 earnings at ($0.04) EPS, FY2026 earnings at $0.00 EPS, FY2027 earnings at ($0.05) EPS and FY2028 earnings at ($0.05) EPS.

Several other analysts have also recently weighed in on the stock. Craig Hallum initiated coverage on shares of Lineage Cell Therapeutics in a research note on Tuesday, August 20th. They issued a “buy” rating and a $4.00 price objective on the stock. D. Boral Capital decreased their price target on Lineage Cell Therapeutics from $3.00 to $2.00 and set a “buy” rating for the company in a research note on Wednesday, November 20th.

Lineage Cell Therapeutics Stock Up 1.1 %

Lineage Cell Therapeutics stock opened at $0.58 on Friday. Lineage Cell Therapeutics has a 12 month low of $0.50 and a 12 month high of $1.61. The stock has a market capitalization of $109.09 million, a price-to-earnings ratio of -4.81 and a beta of 1.16.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Barclays PLC lifted its position in shares of Lineage Cell Therapeutics by 311.3% during the 3rd quarter. Barclays PLC now owns 211,300 shares of the company’s stock valued at $192,000 after acquiring an additional 159,924 shares during the period. Geode Capital Management LLC increased its stake in Lineage Cell Therapeutics by 2.3% in the third quarter. Geode Capital Management LLC now owns 3,679,280 shares of the company’s stock valued at $3,331,000 after purchasing an additional 83,274 shares in the last quarter. State Street Corp raised its holdings in shares of Lineage Cell Therapeutics by 1.8% during the third quarter. State Street Corp now owns 2,608,352 shares of the company’s stock valued at $2,361,000 after purchasing an additional 45,483 shares during the period. Raffles Associates LP raised its holdings in shares of Lineage Cell Therapeutics by 3.4% during the third quarter. Raffles Associates LP now owns 4,507,781 shares of the company’s stock valued at $4,081,000 after purchasing an additional 150,000 shares during the period. Finally, MAI Capital Management boosted its position in shares of Lineage Cell Therapeutics by 2.2% during the 3rd quarter. MAI Capital Management now owns 1,674,679 shares of the company’s stock worth $1,516,000 after purchasing an additional 35,907 shares in the last quarter. 62.47% of the stock is owned by institutional investors and hedge funds.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.